Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.

Original title: “Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion”

Original title: “National Cancer Institute; Notice of Partially Closed Meeting”

At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and a host of antibody-drug conjugates.

Original title: “Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026”

Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.

Original title: “Verastem cancer drug shows early promise in small study”

it takes two to tango the intersection of deubiquitinases and m 6 a modification in cancer

Original title: “It takes two to tango: the intersection of deubiquitinases and m(6)A modification in cancer.”

rare k mers reveal centromere haplogroups underlying human diversity and cancer translocations

Original title: “Rare k-mers reveal centromere haplogroups underlying human diversity and cancer translocations.”

Collaboration to expand personalised cancer immunotherapy

Original title: “NHS Blood and Transplant partners with Northwest Biotherapeutics”

micro nanostructured materials and microfluidic diagnostic platforms enable multimodal detection of circulating tumor cells

Original title: “Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells.”

ablation immunotherapy synergy in cancer mechanisms of the abscopal effect emerging clinical applications and translational roadmaps for next generation onco immunology

Original title: “Ablation-immunotherapy synergy in cancer: mechanisms of the abscopal effect, emerging clinical applications, and translational roadmaps for next-generation onco-immunology.”

The next three months will feature anticipated decisions on a new kind of cancer immunotherapy, as well as medicines important to the futures of Roche, GSK and Gilead.

Original title: “5 FDA decisions to watch in the fourth quarter of 2026”

Traveling hours away from home for a multiyear clinical trial sounds manageable in a Washington conference room. It looks very different when you're the one making that trip while your body is working against you as opposed to having access to the therapy at your own hospital. CANCER TREATMENT DELAYS SURGE ACROSS US AS DOCTOR WARNS SYSTEM ‘NEEDS FIXING IMMEDIATELY’ ... That's why I want the next FDA commissioner to listen to patients like me. We don’t just read about the disease ... Traveling hours away from home for a multiyear clinical trial sounds manageable in a Washington conference room. It looks very different when you're the one making that trip while your body is working against you as opposed to having access to the therapy at your own hospital. CANCER TREATMENT DELAYS SURGE ACROSS US AS DOCTOR WARNS SYSTEM ‘NEEDS FIXING IMMEDIATELY’ ... That's why I want the next FDA commissioner to listen to patients like me. We don’t just read about the disease in books or look at it through a microscope — we live with it every day. A 25-year-old living with Duchenne muscular dystrophy explains why the Senate confirmation fight over FDA nominee Dr. Heidi Overton is personal. Duchenne muscular dystrophy life expectancy rarely extends past 25. A young man living with the rare disease urges the Senate to confirm a patient-centered FDA commissioner. For most Americans, an FDA commissioner is just another name in the news. For the 30 million Americans like me living with a rare disease, that person can decide how many options I have and how much time I have to use them. To be clear: I'm not asking the FDA to abandon science. I respect doctors, clinical trials and hard evidence.

Original title: “Patients with rare diseases need an FDA partner, not another gatekeeper | Fox News”

Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.

Original title: “Grail multicancer detection test wins FDA advisers’ backing”

In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We look at the momentum behind radioligand therapy and how its diagnostic and therapeutic capabilities are improving care for more than 14 million patients worldwide.

Original title: “How radioligand therapy is rewriting cancer care”

tumor data extraction from unstructured medical reports application of an artificial intelligence enhanced tool in the eastern switzerland cancer registry

Original title: “Tumor data extraction from unstructured medical reports: application of an artificial intelligence-enhanced tool in the Eastern Switzerland Cancer Registry.”

Envisagenics’ platform makes use of AI to screen and detect cancer-specific RNA alterations, which Boehringer Ingelheim wants to target through various precision treatment modalities, including multi-specific antibodies, antibody-drug conjugates and T cell engagers.

Original title: “Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics”

Deal strengthens company’s established medicines strategy

Original title: “Grünenthal acquires cancer medicine Stivarga”

According to IMARC Group the global virtual clinical trials market size reached USD 252 5 Million in 2025 and is projected to reach USD 379 0 Million by 2034 expanding at a CAGR of 4 48 during 2026 2034 This ... Press release - IMARC Group - Virtual Clinical Trials Market Size, Share, In-Depth Analysis, Trends and Forecast 2026-2034 - published on openPR.com Advances in targeted therapies, immunotherapies, and precision medicine are reshaping cancer care and pushing sponsors toward trial designs that can accommodate more individualized treatment protocols. The growing understanding of tumor genetics is also expanding demand for niche trials targeting rare and genetically defined cancers, where virtual recruitment models help overcome the patient-scarcity challenges that limit traditional site-based enrollment. This steady growth reflects the deepening integration of advanced imaging technology into veterinary practice, driven by rising pet humanization, escalating chronic disease burden in animals, and the rapid proliferation of specialized veterinary hospitals and clinics globally.

Original title: “Virtual Clinical Trials Market Size, Share, In-Depth Analysis, Trends and Forecast 2026-2034”

Delivering therapeutics directly to tumors, as in the case of Replimune’s recently approved Tudriqev and Amgen’s Imlygic, holds advantages, especially when cancer is caught early, but challenges remain before the method becomes a mainstay in treatment.

Original title: “Citing Replimune approval, experts say localized cancer meds could redefine care”

genetic and molecular determinants of cancer therapy related cardiovascular toxicity

Original title: “Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.”